CHURCHILL MANAGEMENT Corp reduced its position in Quest Diagnostics Incorporated (NYSE:DGX) by 9.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,196 shares of the medical research company’s stock after selling 2,108 shares during the quarter. CHURCHILL MANAGEMENT Corp’s holdings in Quest Diagnostics were worth $2,288,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in DGX. Hall Laurie J Trustee bought a new position in shares of Quest Diagnostics in the 3rd quarter worth about $34,000. Hudock Inc. bought a new stake in shares of Quest Diagnostics in the 3rd quarter valued at about $34,000. RMR Wealth Builders acquired a new stake in Quest Diagnostics in the 2nd quarter valued at about $35,000. Princeton Global Asset Management LLC grew its holdings in Quest Diagnostics by 100.0% during the third quarter. Princeton Global Asset Management LLC now owns 320 shares of the medical research company’s stock worth $37,000 after purchasing an additional 160 shares during the period. Finally, Planned Solutions Inc. acquired a new position in Quest Diagnostics during the third quarter worth approximately $45,000. Hedge funds and other institutional investors own 78.87% of the company’s stock.

Several brokerages have recently weighed in on DGX. Jefferies Financial Group upped their price target on shares of Quest Diagnostics from $125.00 to $134.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. Zacks Investment Research upgraded shares of Quest Diagnostics from a “hold” rating to a “strong-buy” rating and set a $130.00 price target for the company in a research report on Tuesday, September 22nd. Wells Fargo & Company restated a “hold” rating on shares of Quest Diagnostics in a research report on Friday, October 23rd. Argus upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating and set a $135.00 price target on the stock in a research report on Wednesday, October 21st. Finally, Morgan Stanley cut shares of Quest Diagnostics from an “overweight” rating to an “equal weight” rating in a research note on Thursday, December 17th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $126.83.

In related news, CEO Stephen H. Rusckowski sold 291,997 shares of the company’s stock in a transaction that occurred on Friday, October 16th. The stock was sold at an average price of $120.00, for a total transaction of $35,039,640.00. Following the transaction, the chief executive officer now directly owns 529,744 shares of the company’s stock, valued at approximately $63,569,280. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Daniel Stanzione sold 11,223 shares of the stock in a transaction that occurred on Monday, November 23rd. The stock was sold at an average price of $126.30, for a total value of $1,417,464.90. Following the completion of the transaction, the director now owns 33,951 shares in the company, valued at approximately $4,288,011.30. The disclosure for this sale can be found here. Insiders sold 395,426 shares of company stock valued at $47,604,325 over the last 90 days. Corporate insiders own 1.49% of the company’s stock.

Shares of NYSE:DGX opened at $125.45 on Thursday. The business has a fifty day simple moving average of $122.27 and a 200 day simple moving average of $119.90. Quest Diagnostics Incorporated has a 12-month low of $73.02 and a 12-month high of $131.81. The firm has a market cap of $16.91 billion, a P/E ratio of 15.51, a P/E/G ratio of 0.42 and a beta of 1.08. The company has a quick ratio of 1.32, a current ratio of 1.40 and a debt-to-equity ratio of 0.62.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings data on Thursday, October 22nd. The medical research company reported $4.31 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.75 by $0.56. Quest Diagnostics had a net margin of 13.22% and a return on equity of 19.23%. The company had revenue of $2.79 billion during the quarter, compared to analysts’ expectations of $2.71 billion. During the same period in the prior year, the company posted $1.76 earnings per share. Quest Diagnostics’s revenue for the quarter was up 42.6% compared to the same quarter last year. As a group, equities research analysts expect that Quest Diagnostics Incorporated will post 10.97 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 3rd. Shareholders of record on Wednesday, January 20th will be paid a $0.56 dividend. This represents a $2.24 annualized dividend and a yield of 1.79%. The ex-dividend date is Tuesday, January 19th. Quest Diagnostics’s dividend payout ratio (DPR) is presently 34.15%.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Featured Story: Operating Income

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.